A Protein Kinase B inhibitor will be taken into clinical development by AstraZeneca, following a successful collaboration with the biotechnology company Astex Therapeutics.
The PKB programme, from which the clinical candidate was selected, stemmed from collaborative research originally carried out by The Institute of Cancer Research, CRT and Astex.
We identify, develop and commercialise promising ideas into successful cancer therapeutics, diagnostics and enabling technologies.
iOnctura SA announces the first patient has been dosed in a Phase Ib clinical trial of IOA-289 in metastatic pancreatic cancer.
iOnctura SA announced the start of clinical development for its second program, a next generation autotaxin inhibitor designated IOA-289.
